Compare · MMM vs PSTV
MMM vs PSTV
Side-by-side comparison of 3M Company (MMM) and PLUS THERAPEUTICS Inc. (PSTV): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both MMM and PSTV operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- MMM is the larger of the two at $83.37B, about 3238.5x PSTV ($25.7M).
- PSTV has been more active in the news (12 items in the past 4 weeks vs 10 for MMM).
- MMM has more recent analyst coverage (25 ratings vs 3 for PSTV).
- Company
- 3M Company
- PLUS THERAPEUTICS Inc.
- Price
- -
- -
- Market cap
- $83.37B
- $25.7M
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NYSE
- NASDAQ
- IPO
- News (4w)
- 10
- 12
- Recent ratings
- 25
- 3
3M Company
3M Company develops, manufactures, and markets various products worldwide. It operates through four business segments: Safety and Industrial, Transportation and Electronics, Health Care, and Consumer. The Safety and Industrial segment offers personal safety products, industrial adhesives and tapes, abrasives, closure and masking systems, electrical markets, automotive aftermarket, and roofing granules to industrial, electrical, and safety markets. The Transportation and Electronics provides electronics, such as display materials and systems, electronic materials solutions; automotive and aerospace, and commercial solutions; advanced materials; and transportation safety products to transportation and electronic original equipment manufacturer customers. The Health Care segment offers medical and surgical supplies, skin health and infection prevention products, oral care, separation and purification sciences, health information systems, drug delivery systems, and food safety products to healthcare industry. The Consumer segment provides home improvement, home care, and consumer health care products, as well as stationery and office supplies to various consumers. This segment is also involved in the retail auto care business. It offers its products through various e-commerce and traditional wholesalers, retailers, jobbers, distributors, and dealers, as well as directly to users. 3M Company has a strategic collaboration with Merry Maids in residential cleaning sector; and collaborations with The Infectious Disease Research Institute and Duke Human Vaccine Institute to create a vaccine candidate with potential to provide protection against multiple variants of SARS-CoV-2. The company was founded in 1902 and is headquartered in St. Paul, Minnesota.
PLUS THERAPEUTICS Inc.
Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer and other diseases. Its lead drug candidate is Rhenium NanoLiposomes, a patented radiotherapy for patients with recurrent glioblastoma, which is in the Phase 1 dose-finding clinical trial. The company is also developing DocePLUS, a patented chemotherapy for patients with solid tumors that is in Phase 1 clinical trial; and DoxoPLUS, a generic chemotherapy for patients with ovarian cancer. It has a license agreement with NanoTx, Corp. to develop and commercialize NanoTx's glioblastoma treatment. The company was formerly known as Cytori Therapeutics, Inc. and changed its name to Plus Therapeutics, Inc. in July 2019. Plus Therapeutics, Inc. was founded in 1996 and is headquartered in Austin, Texas.
Latest MMM
- 3M upgraded by Analyst with a new price target
- 3M and Microsoft announce strategic partnership to advance AI data center infrastructure and enterprise transformation
- Scotch™ Brand launches Scotch Kids® Tape for young creators
- 3M Announces Upcoming Investor Event
- 3M Young Scientist Challenge Names 10 Finalists for 2026 National Competition
- Group President Bauer Wendy A exercised 7,952 shares at a strike of $159.96 and covered exercise/tax liability with 3,558 shares, increasing direct ownership by 94% to 9,086 units (SEC Form 4)
- 3M and Discovery Education announce 37 State Merit Winners and four Honorable Mentions in 2026 3M Young Scientist Challenge
- 3M joins Cadillac Formula 1® Team as Official Material Science Partner to accelerate racing performance
- 3M and Airbus announce agreement to advance A220 passenger comfort and aircraft performance through advanced insulation technology
- 3M launches Ask 3M, an AI-powered tool for faster access to technical expertise
Latest PSTV
- Plus Therapeutics and Genomic Testing Cooperative Partner to Integrate Next-Generation Sequencing Into the CNSide® CSF Assay Platform
- Plus Therapeutics Highlights NCCN CNS Cancers Guidelines Update and Reinforces Clinical Role of CNSide® in Leptomeningeal Metastases Monitoring
- Director Andrews Ronald Asbury converted options into 922 shares (SEC Form 4)
- Chief Financial Officer Sims Andrew John Hugh Macintyre converted options into 2,985 shares, increasing direct ownership by 43% to 9,941 units (SEC Form 4)
- Director Hawkins Richard J converted options into 922 shares, increasing direct ownership by 152% to 1,529 units (SEC Form 4)
- Director Van Es-Johansson An converted options into 922 shares (SEC Form 4)
- Director Clowes Howard converted options into 922 shares, increasing direct ownership by 87% to 1,981 units (SEC Form 4)
- Chief Executive Officer Hedrick Marc H converted options into 16,439 shares, increasing direct ownership by 59% to 44,483 units (SEC Form 4)
- Director Guse Kyle converted options into 922 shares (SEC Form 4)
- Plus Therapeutics Provides Mid-Year Business Update Including Corporate Rebranding